Skip to main content
Premium Trial:

Request an Annual Quote

Signature BioScience Names New CSO, Finance Director

NEW YORK, May 1 – Protein structure determination company Signature BioScience said Tuesday it had appointed David Spellmeyer chief scientific officer and vice president of drug discovery.

Spellmeyer will be in charge of developing Signature BioScience’s new drug discovery efforts and validating the company’s technology.

Previously Spellmeyer was executive director at DuPont Pharmaceuticals Research Laboratories, where he oversaw the computational chemistry aspects of drug discovery and information technologies.

The San Francisco-based company also named Nancy Pecota senior director of finance and administration. Pecota was recently director of finance and accounting at Aclara BioSciences, where she was part of the management team that successfully took the company public.

Signature BioScience, an early stage proteomics company, has adapted telecommunications and computer chip technology to determine the structure and homology of classes of proteins.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.